There is some controversy regarding the optimal frontline treatment for patients with pancreatic cancer. There is no debate that patients with elevated CA 19-9, which indicates worse prognosis and increased risk of micrometastatic disease, should receive neoadjuvant chemotherapy. Watch here . . .
Michael A. Choti, MD, chief of surgery, Banner MD Anderson Cancer Center, discusses the role of upfront surgery in pancreatic adenocarcinoma.